No­var­tis gains pri­or­i­ty re­view for SMA gene ther­a­py as in­vestors grap­ple with stick­er shock

An FDA ap­proval for the world’s first $4 mil­lion gene ther­a­py could ar­rive in as soon as five months.

No­var­tis says that reg­u­la­tors have opened …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.